We recently showed that monoclonal antibodies (mAbs) against β 2 M have a remarkably strong apoptotic effect on myeloma cells. The mAbs induced apoptosis by recruiting MHC class I to lipid rafts, activated JNK, and inhibited PI3K/Akt and ERK pathways.
Introduction
Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of monoclonal plasma cells in the bone marrow 1, 2 . Binding of myeloma cells to bone marrow stromal cells triggers transcription and secretion of cytokines from stromal cells, which not only promote growth, survival and migration of myeloma cells but also confer resistance to conventional chemotherapy 1-3-4 . Previous studies have shown that cytokines such interleukin-6 (IL-6) and insulin-like growth factor-I (IGF-I) are the major growth and survival factors for myeloma cells [5] [6] [7] [8] , and play a crucial role in the onset of plasma cell tumors in mice 9 . Specifically, IL-6 binds to gp80 (CD80, IL-6 receptor; IL6R), which is expressed on most myeloma cell lines and patient tumors, and induces phosphorylation and dimerization of gp130. Phosphorylation of gp130 in turn activates multiple downstream signaling pathways, such as JAK/STAT3 10 , Ras/Raf/MAP kinases (MAPK) 11 , and PI3K/Akt 12 , and triggers myeloma cell growth, survival, and drug-
resistance. Likewise, IGF-I binds to IGF-I receptor (IGF-IR) and exerts its anti-apoptotic effects on myeloma cells via activating anti-apoptotic signaling pathways, such as
Ras/Raf/MAPK and PI3K/Akt 13, 14 . Therefore, it may be useful to disrupt growth factormediated anti-apoptotic signaling pathways for myeloma therapy, which might provide the framework to develop and validate novel antimyeloma agents to overcome drugresistance and improve patient outcome.
Lipid rafts, cholesterol-and glycosphingolipid-enriched dynamic patches in the plasma membrane, organize the plasma membrane into functional units 15 . These raft domains act as platforms for conducting different signals into cells for various functions, including cytokine-mediated growth signaling 16 . Integral proteins in the cellular membrane, such as caveolins and flotillins, can modify lipid rafts structurally and functionally, and may therefore affect subsequent cellular functions [17] [18] . Some reports have shown that growth factors, such as IL-6, induce translocation of their receptors to lipid rafts and confer protection against dexamethasone treatment 19, 20 . Remacle-Bonnet and coworkers 21 observed that lipid rafts segregated pro-apoptotic from anti-apoptotic IGF-IR-mediated signaling in tumor cells, suggesting that the localization of growth factor receptors outside lipid rafts might be involved in the transduction of apoptotic signals.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
Furthermore, we and others demonstrated that lipid rafts might be involved in anti-β 2 -microglobulin (β 2 M), major histocompatibility complex (MHC) class II, and CD20 mAbinduced apoptosis in tumor cells [22] [23] [24] [25] , indicating that lipid rafts might also be an important platform for the mAb-mediated tumoricidal effects on myeloma cells.
We have recently shown that anti-β 2 M mAbs have remarkable tumoricidal activity on myeloma cells both in vitro and in xenograft myeloma SCID mouse models 25 . We demonstrated that anti-β 2 M mAbs induced myeloma cell apoptosis by recruiting MHC class I molecules to lipid rafts, activated JNK and inhibited PI3K/Akt and ERK, compromised mitochondrial integrity, and activated the caspase-9-dependent cascade. To further elucidate the mechanisms of mAb-induced inhibition of PI3K/Akt and ERK signaling pathways and the inability of IL-6 and IGF-I to protect myeloma cells from apoptosis, we examined the localization of cytokine receptors and their signaling pathways in myeloma cells with or without treatment with anti-β 2 M mAbs. We confirmed that IL-6 and IGF-I signaling pathways depend on lipid rafts and showed that anti-β 2 M mAbs recruit MHC class I to and exclude cytokine receptors from lipid rafts. Recombinant human IL-6 and IGF-I were purchased from R&D Systems (Minneapolis, MN). Mouse IgG1 and dexamethasone were purchased from Sigma (St. Louis, MO).
Materials and methods

Myeloma cell lines, primary myeloma cells, and reagents
Monoclonal antibodies against HLA-ABC (clone W6/32) were purchased from Serotec Ltd.
Generation of β 2 M-specific monoclonal antibodies (mAbs)
We generated a panel of β 2 M-specific monoclonal antibodies as previously described 25 .
Among of them, D1 and E6 (isotype IgG1) were chosen for this study because of their strong antimyeloma activities.
Apoptosis assays
Cells were incubated with 50 µg/mL of β 2 M-specific mAbs D1 or E6, or mouse IgG1 as 
RNA interference
Double-stranded, 21-mer siRNA corresponding to β 2 M was designed with the following sense and antisense sequences: sense: 5′-GAUUCAGGUUUACUCAC GUdTdT-3′; and antisense: 5′-ACGUGAGUAAACCUGAAUCdTdT-3′, starting from nucleotide 91 of the 
Isolation of lipid rafts by sucrose density gradient ultracentrifugation
The Caveolae/Raft Isolation Kit (Sigma) was used to isolate lipid rafts as low density, detergent-resistant membrane fractions by sucrose density gradient centrifugation using 1% Triton-X-100. Briefly, 5 × 10 7 cells were lysed for 30 min in ice-cold lysis buffer.
Cell lysates were mixed with OptiPrep to 35%, placed at the bottom of the ultracentrifuge tube, overlaid with 4 layers of 30 to 0% OptiPrep, and centrifuged at 200,000 × g using a TFT 65.13 rotor (Kontron Instruments) for 4 h at 4°C. Nine fractions (1 mL each) were collected from the top to the bottom of the gradients. The lipid rafts determined with CTB binding for GM1 gangliosides and with a caveolin-1 specific antibody were found in fractions 2 to 5. Non-lipid raft fractions were present in fractions 7 to 9, which were negatively stained by GM1 gangliosides and caveolin-1.
Cholesterol depletion
For cholesterol depletion, myeloma cells were preincubated with 5 mM of methyl-β-cyclodextrin (MCD, purchased from Sigma) for 30 min, washed, and incubated with or without β 2 M-specific mAbs (50 µg/mL) for 48 h, followed by cell apoptosis analysis.
Immunoprecipitation assay
Myeloma cells were incubated with IL-6 (10 ng/mL) or IGF-I (50 ng/mL) with or without 50 µg/mL of β 2 M-specific mAbs or mouse IgG1 on ice for 30 min, washed, and lysed in 1 mL RIPA buffer (10 mM Tris-HCL buffer, pH 7.5, 1% NP-40, 0.25% deoxycholate wt/vol, 2 mM EDTA, 10 mM orthovanadate). Cell lysates were incubated with antibodies specific to caveolin-1, gp130, or IGF-IRβ, followed by precipitating with protein GSepharose in a 50% wt/vol slurry. Immunoprecipitated proteins were washed in RIPA buffer, subjected to SDS-PAGE, and immunoblotted with specific antibodies against caveolin-1, gp130, IGF-IRβ, or MHC class I molecules.
Western blotting analysis
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Cells were cultured with IL-6 (10 ng/mL) or IGF-I (50 ng/mL) with or without 50 µg/mL of β 2 M-specific mAbs, harvested, washed, and lysed with lysis buffer (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 5 mM NaN 3 , 1% Triton-X-100, 1% NP-40, 1 × protease inhibitor cocktail). Cell lysates were subjected to SDS-PAGE, transferred to polyvinylidene difluoride membrane, and immunoblotted with antibodies against phosphorylated or non-phosphorylated IL-6R, JAK, STAT3, Akt, Raf, ERK1/2, IGF-IRβ, IRS-1, ASK1, MLK3, MEKK-1, MKK4, MKK7, and JNK (Cell Signaling Technology, Inc., Beverly. MA, and Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Secondary antibodies conjugated to horseradish peroxidase were used for detection, followed by enhanced chemiluminescence (Pierce, Rockford, IL) and autoradiography. For protein quantification, blots were scanned and analyzed by spot densitometry, and results were expressed as average value of pixels enclosed (AVG), calculated as the sum of all the pixel values after background correction divided by area.
Statistical analysis
All data are shown as means ± standard deviation. The Student t test was used to compare various experimental groups. Significance was set at P < .05.
Results
Growth and survival factors do not abrogate β 2 M-specific mAb-induced myeloma cell apoptosis
Previous studies showed that addition of IL-6 protected myeloma cells from dexamethasone-induced apoptosis. As we previously reported that anti-β 2 M mAbs induced apoptosis in myeloma cells, we asked whether IL-6 would also protect myeloma cells from the mAb-induced apoptosis. In our experiments, β 2 M-specific mAbs (50 µg/mL) were added to cultures of myeloma cell lines ARP-1 and MM.1S, with or without addition of 10 ng/mL of human IL-6. Cell apoptosis was examined 48 h later by Annexin-V staining assay. As shown in Figure 1A , β 2 M-specific mAb D1, but not mouse
IgG1 (data not shown), and dexamethasone effectively induced apoptosis in myeloma
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From cells. The addition of IL-6 did not affect mAb-induced apoptosis but significantly undermined dexamethasone-induced cell death (P < .05; Fig 1A) . Increasing IL-6 concentration to 100 ng/mL still failed to protect myeloma cells from β 2 M-specific mAbinduced apoptosis (data not shown). Likewise, β 2 M-specific mAbs (P < .01, compared with medium controls) but not dexamethasone killed two IL-6-dependent cell lines XG1 and ANBL-6 in their culture with the addition of exogenous IL-6 ( Figure 1B ; 2 ng/mL for normal culture, or 20 ng/mL for high concentration; data not shown). However, in the absence of IL-6, both the mAb and dexamethasone induced apoptosis in these two cell lines (P < .05, compared with medium controls).
IGF-I is another important growth and survival factor for myeloma cells. Therefore, we examined the effect of IGF-I on β 2 M-specific mAb-induced apoptosis. Myeloma cells were cultured with the β 2 M-specific mAbs with or without the addition of IGF-I (50 ng/mL). Again, results showed that IGF-I did not affect β 2 M-specific mAb-induced cell death but reduced dexamethasone-mediated apoptosis in myeloma cells ( Figure 1A) .
We next investigated the activity of IL-6 and IGF-I on freshly isolated primary tumor cells from patients with MM. Purified myeloma cells obtained from bone marrow aspirates of four newly diagnosed, previously untreated patients with MM were examined and showed sensitivity to β 2 M-specific mAb-mediated killing (data not shown). As shown by the representative results depicted in Figure 1C , addition of 10 ng/mL IL-6 or 50 ng/mL IGF-I to the cultures had no effect on β 2 M-specific mAb-induced apoptosis in the primary myeloma cells, whereas both IL-6 and IGF-I significantly reduced the percentages of apoptotic cells induced by dexamethasone (P < 0.05). Similar results were obtained with primary myeloma cells from all four patients ( Figure 1D ). Taken together, these results indicate that although IL-6 and IGF-I are potent protectors of myeloma cells against dexamethasone, they could not abrogate mAb-mediated apoptotic activities in myeloma cells.
To confirm the importance of surface β 2 M as the target for β 2 M-specific mAb-induced but not for dexamethasone-induced apoptosis and to exclude the involvement of surface β 2 M in IL-6-mediated protection of apoptosis in myeloma cells, small interfering RNA For personal use only. on August 31, 2017. by guest www.bloodjournal.org From (siRNA) specific for human β 2 M gene was synthesized and used to knockdown the β 2 M expression in myeloma cells. We were able to achieve 70 to 80% reduction of surface β 2 M and HLA-ABC protein expression on myeloma cells on day 3 after transfection with β 2 M-specific siRNA but not with control siRNA or mock transfection ( Fig. 2A) . Therefore, we examined the localization of IL-6 and IGF-I receptors on myeloma cells before and after β 2 M-specific mAb treatment. Myeloma cells were incubated with IL-6 (10 ng/mL) or IGF-I (50 ng/mL), with or without β 2 M-specific mAbs (50 µg/mL). Mouse IgG1 was used as control for the mAbs. Cells without treatment were used as control.
Detection of β
After 30 min of treatment, cell lysates were prepared and separated using a discontinuous sucrose gradient ultracentrifugation followed by immunoblotting with specific antibodies.
In the light buoyant density fractions, fractions 2 to 5 were positive for GM1 gangliosides, identified by CTB binding, and contain lipid rafts, which stained positive for caveolin-1, a raft-associated protein absent in the non-raft fractions 7 to 9 ( Figure 3) . Figure 3A , IL-6R gp130, IGF-IRβ, IRS-1 (an IGF-IR substrate), and MHC class-I were detected in the non-raft fractions in control myeloma cells. Upon IL-6 or IGF-I stimulation, the majority of gp130, IGF-IRβ, and IRS-1 molecules were detected in the raft fractions, whereas MHC class-I were located in the non-raft fractions, indicating
As shown in
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From that the cytokine receptors and substrates were relocalized to lipid rafts for signaling ( Figure 3B) . Surprisingly, in cells treated with both anti-β 2 M mAb (D1) and IL-6 or IGF-I ( Figure 3D ), but not mouse IgG1 and IL-6 or IGF-I (Figure 3C) , most gp130 and IGF-IRβ were detected in the non-lipid raft fractions and fewer IRS-1 molecules were present in the raft fractions, while MHC class I were recruited to the lipid raft fractions as we showed previously. These findings suggest that the cytokine receptors and their substrate were excluded from the lipid rafts as a result of β 2 M-specific mAb-mediated recruitment of MHC class I to the rafts. 
Disruption of lipid rafts abrogates both IL-6 signaling and β 2 M-specific mAb apoptotic effects in myeloma cells
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To confirm the importance of the lipid rafts in IL-6 signaling and protection of myeloma cell apoptosis, we treated myeloma cells with MCD, an agent that disrupts the structure of lipid rafts in cell membrane. As shown in Figure 4D , MCD treatment abrogated IL-6-mediated protection of myeloma cell apoptosis induced by dexamethasone (P < .05 to P < .01), indicating that lipid rafts are crucial for IL-6R signaling to activate anti-apoptotic pathways in myeloma cells. As expected, MCD also abrogated β 2 M-specific mAbinduced apoptosis in myeloma cells. Taken together, these results demonstrate that the β 2 M-specific mAbs induced dominant changes in the distribution of MHC-I molecules and cytokine receptors in lipid rafts. Myeloma cells were treated with IL-6 without or with β 2 M-specific mAbs or mouse IgG1. Western blotting analysis was performed using specific antibodies against phosphorylated (p) or nonphosphorylated IL-6R, JAK1/1, STAT3, Akt, Raf, and ERK1/2. As shown in Figure 5A , treatment of cells with IL-6 or IL-6 plus mouse IgG1 (data not shown) induced phosphorylation of IL-6R (pIL-6R), and upregulated the levels of pJAK1/2, pSTAT3, pAkt, pRaf, and pERK, indicating that IL-6 activated JAK/STAT3, PI3K/Akt, and Ras/Raf/ERK signaling pathways. In contrast, β 2 M-specific mAb treatment inhibited IL-6-induced phosphorylation of IL-6R and the kinases. These results are supported by protein quantification data of phosphorylated IL-6R and kinases (P < .05 and P < .01; Figure 5B ). The levels of nonphosphorylated IL-6R and kinases remained unchanged. After 60 min of treatment, the kinase activities were undetectable in β 2 M-specific mAb-treated myeloma cells.
Second, we examined the impact of β 2 M-specific mAbs on IGF-I-mediated signaling pathways, including PI3K/Akt and Ras/Raf/ERK. As shown in Figure 5C , IGF-I or IGF- Figure 5D ; P < .05 and P < .01). These results indicated that β 2 M-specific mAbs abrogate growth factor-mediated anti-apoptotic signaling pathways in myeloma cells.
M-specific mAbs activate the upstream kinases of JNK signaling pathway
Since our previous studies demonstrated that β 2 M-specific mAbs induced myeloma cell apoptosis via JNK activation, we examined the activities of kinases upstream of JNK signaling pathway, including ASK1, MLK3, MEKK1, and MKK4/7. As shown in Figure   6A -B, treatment of myeloma cells with β 2 M-specific mAbs significantly increased the level of phosphorylated ASK1, MLK3, MEKK1, MKK4, and MKK7 (P < .01). The phosphorylation of these kinases was observed as early as 15 min and lasted for 2 h after the treatment, although their kinetics were slightly different. As a consequence, protein levels of phosphorylated JNK (pJNK) were increased in β 2 M-specific mAb-treated myeloma cells. These results further confirm that β 2 M-specific mAb activate the JNK signaling pathway.
DISCUSSION
The importance of IL-6 and IGF-I in the pathogenesis of MM is well documented [5] [6] [7] [8] .
Recent studies have also shown that these cytokines play an important role in myeloma cell survival and protect the tumor cells from chemotherapy drugs, such as dexamethasone-induced apoptosis 19 . IL-6 binds to its receptor gp80, induces phosphorylation and dimerization of gp130, and activates JAK/STAT3, PI3K/Akt, and Ras/Raf/ERK pathways in myeloma cells [10] [11] [12] . As a consequence, MKK4/7 phosphorylates and activates JNK, leading to myeloma cell apoptosis. However, these findings do not explain why PI3K/Akt and ERK pathways were inhibited by β 2 M-specific mAbs.
To further define the mechanisms underlying β 2 M-specific mAb-induced apoptosis and the inability of IL-6 and IGF-I to counteract the effects of the mAbs on myeloma cells, we focused on lipid rafts because they are involved in cell growth and apoptosis signaling 15, 16 . IL-6 binds to IL-6R, recruits the receptors to lipid rafts, and stimulates downstream anti-apoptotic signaling pathways to resist dexamethasone treatment. In this study, we Moreover, we observed that MHC class I molecules replaces gp130, IGF-IRβ, and IRS-1 in lipid rafts, because these receptors and the substrates were found in the non-raft fractions after β 2 M-specific mAb treatment. These findings indicate that β 2 M-specific mAbs exclude growth factor receptors from lipid rafts and abrogate IL-6-or IGF-Imediated JAK/STAT3, PI3K/Akt, and Ras/Raf/ERK pathway signaling, which are otherwise constitutively activated in myeloma cells. Thus, these results provide a plausible explanation for anti-β 2 M mAb-induced inhibition of PI3K/Akt and ERK pathways in myeloma cells. Our results also showed that disruption of lipid rafts by MCD abrogates both β 2 M-specific mAb-induced apoptotic effects on myeloma cells and IL-6-mediated protection against dexamethasone treatment, indicating that the integrity of lipid rafts is important for both pro-apoptotic and anti-apoptotic signaling.
In conclusion, this study demonstrated that anti-β 2 M mAbs induce cell death via recruiting MHC class I molecules to lipid rafts, which not only activate JNK via Lyn and PLCγ2, but also inhibit PI3K/Akt and ERK pathways by excluding IL-6 and IGF-I receptors from lipid rafts and disrupting their signaling pathways (Figure 7) . These findings explain why the cytokines protect myeloma cells from dexamethasone-induced apoptosis but had no effect on cell death induced by the mAbs. Thus, this study further defines the tumoricidal mechanism of the mAbs and provides strong evidence to support the potential and implication of these mAbs as therapeutic agents for myeloma. 
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